Señales en vivo de NLSP | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 may 2024 @ 16:00):

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders...

Stats
Volumen de hoy	82 237.00
Volumen promedio	607 918
Capitalización de mercado	5.30M
EPS	$0 ( 2023-08-04 )
Próxima fecha de ganancias	( $0 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.270
ATR14	$0.00200 (1.51%)

Volumen Correlación

Largo: -0.08 (neutral)

Corto: 0.80 (moderate)

Signal:(48.241) Neutral

NLS Pharmaceutics AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NLS Pharmaceutics AG Correlación - Moneda/Commodity

-0.62
( weak negative )

-0.65
( weak negative )

0.00
( neutral )

0.71
( moderate )

NLS Pharmaceutics AG Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$-11 408.00 (0.00 %)
EPS:	$-0.840

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-11 408.00 (0.00 %)
EPS:	$-0.840

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.014

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.270

Financial Reports:

No articles found.

NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Actualizaciones en tiempo real para NLS Pharmaceutics AG [NLSP]

Upcoming Earnings Alert